Shawn Wilker, MD
Ophthalmology · Beachwood, OHNPI 1578691515
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,218 of the $3,998 with a category attached, or 80.5%. 17 manufacturers reported payments, led by Novartis at 31.7% of the total. Reporting peaked in 2019 at $1,437 and has fallen 79.8% since, to $290 in 2025.
Across 78 payments — averaging $51.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Regeneron Healthcare Solutions, Inc.$632
- Genentech USA, Inc.$426
- Apellis Pharmaceuticals, Inc.$398
- Astellas Pharma US Inc$273
- AbbVie$158
- plus $845 from 11 others
Across 8 payments — averaging $55,642 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$445K
What the payments were for
- Travel & lodging$67817%
- Food & beverage$3,21880%
- Gifts$1023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $1,266 |
| Regeneron Healthcare Solutions, Inc. | 13 | $632 |
| Genentech USA, Inc. | 9 | $426 |
| Apellis Pharmaceuticals, Inc. | 12 | $398 |
| Astellas Pharma US Inc | 8 | $273 |
| AbbVie | 7 | $158 |
| Alimera Sciences, Inc. | 2 | $146 |
| Coherus Oncology, Inc. | 1 | $135 |
| Bausch & Lomb Americas Inc. | 2 | $116 |
| Regeneron | 1 | $113 |
| Carl Zeiss Meditec, Inc. | 1 | $102 |
| Genentech, Inc. | 1 | $93 |
| Alcon | 1 | $69 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Biogen | 1 | $19 |
| Notal Vision, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEOVU$445
- EYLEA$379
- VABYSMO$280
- SUSVIMO$143
- EYLEA HD$139
- Cimerli$135
- Iluvien$129
- BUPARLISIB$122
- CLARUS 500 Fundus Camera$102
- XIPERE$100
How this compares
$3,998 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $4,228 |
| Prednisolone Acetate | 87 | $3,621 |
| Ketorolac Tromethamine | 74 | $1,204 |
| Ofloxacin | 52 | $640 |
| Latanoprost | 36 | $278 |
| Timolol Maleate | 20 | $146 |
| Brimonidine Tartrate | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Beachwood
- Lawrence SingermanBeachwood$599K
- Hang PhamBeachwood$10K
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.